Alternativ splicing av pre-mRNA ger upphov till proteindiversitet. Histonmodifieringar kopplas till den alternativa splicingens reglering genom adaptorsystem som overfor den epigenetiska informationen direkt till splicingfaktorerna. De cis- agerande RNA- elementen pa exoner och introner med tillhorande trans- reglerande splicingfaktorer paverkas darfor direkt av specifika histonmodifieringar. En sammankopplande integrerad modell over en rad DNA- baserade processer foreslas. Denna komplexa modell ger en bild av interaktioner och paverkan mellan dessa delar. Kromatin remodellering kravs for bildandet av eukromatin. Nukleosomers placering vid exonrika regioner med specifika modifieringsmonster pekar ut exonerna samt mojliggor inbindning av RNA polymeras II som med sin CTD doman rekryterar bade splicing- och modifieringsfaktorer. Transkriptionshastigheten paverkas av nukleosomplaceringen vilket i sin tur paverkar rekrytering av spliceosomens komponenter, andra trans- agerande regulatorer och aven pre-mRNA sekvensens sekundarstruktur. Kromatin- adaptorkomplex laser av specifika histonmodifieringar och overfor informationen till splicingapparaten. Detta skapar mojlighet till den viktiga cell- och vavnadsspecifika alternativa splicingens reglering. I den integrerade modellen blir komplexiteten tydligare dar alla dessa processer interagerar med varandra och de cis- regulatoriska sekvenserna pa premRNA transkriptet. / Alternative splicing of pre-mRNA generates protein diversity. Histone modifications are connected to the regulation of alternative splicing through adaptor systems that transfers the epigenetic information directly to the splicing factors. The cis- acting RNA elements on the exons and introns together with the trans- regulating splicing factors are therefore directly affected of specific histone modifications. An integrated model over several DNA process mechanisms is suggested. This complex model explains the interactions of the different parts and how they affect each other. Chromatin remodelers are required to obtain euchromatin. Nucleosome positioning at exon rich regions with a specific modification pattern point out where the exons are, and this enable the RNA polymerase II to find and bind to the DNA. It’s CTD domain recruits both splicing- and modifications factors. The transcription rate is also affected of the nucleosome positioning and that in turn affects the recruitment of the components of the spliceosomen, other trans- acting regulators and even the formation of the secondary structure of the pre-mRNA transcript. Chromatin- adaptor complex reads specific histone modifications and transfers this information to the splicing apparatus. All this creates the possibility to regulate important cell- and tissue specific alternative splicing patterns. The integrated model makes the complex processes more clearer when all these integrates with each other and the cis- acting regulating elements on the pre-mRNA transcript.

Cellular function and physiology are largely established through regulated gene expression. The first step in gene expression, transcription of the genomic DNA into RNA, is a process that is highly aligned at the levels of initiation, elongation and termination. In eukaryotes, protein-coding genes are exclusively transcribed by RNA polymerase II (Pol II). Upon transcription of the first 15-20 nucleotides (nt), the emerging nascent RNA 5’ end is modified with a 7-methylguanosyl cap. This is one of several RNA modifications and processing steps that take place during transcription, i.e. co-transcriptionally. For example, protein-coding sequences (exons) are often disrupted by non-coding sequences (introns) that are removed by RNA splicing. The two transesterification reactions required for RNA splicing are catalyzed through the action of a large macromolecular machine, the spliceosome. Several non-coding small nuclear RNAs (snRNAs) and proteins form functional spliceosomal subcomplexes, termed snRNPs. Sequentially with intron synthesis different snRNPs recognize sequence elements within introns, first the 5’ splice site (5‘ SS) at the intron start, then the branchpoint and at the end the 3’ splice site (3‘ SS). Multiple conformational changes and concerted assembly steps lead to formation of the active spliceosome, cleavage of the exon-intron junction, intron lariat formation and finally exon-exon ligation with cleavage of the 3’ intron-exon junction. Estimates on pre-mRNA splicing duration range from 15 sec to several minutes or, in terms of distance relative to the 3‘ SS, the earliest detected splicing events were 500 nt downstream of the 3‘ SS. However, the use of indirect assays, model genes and transcription induction/blocking leave the question of when pre-mRNA splicing of endogenous transcripts occurs unanswered. In recent years, global studies concluded that the majority of introns are removed during the course of transcription. In principal, co-transcriptional splicing reduces the need for post-transcriptional processing of the pre-mRNA. This could allow for quicker transcriptional responses to stimuli and optimal coordination between the different steps. In order to gain insight into how pre-mRNA splicing might be functionally linked to transcription, I wanted to determine when co-transcriptional splicing occurs, how transcripts with multiple introns are spliced and if and how the transcription termination process is influenced by pre-mRNA splicing. I chose two yeast species, S. cerevisiae and S. pombe, to study co-transcriptional splicing. Small genomes, short genes and introns, but very different number of intron-containing genes and multi-intron genes in S. pombe, made the combination of both model organisms a promising system to study by next-generation sequencing and to learn about co-transcriptional splicing in a broad context with applicability to other species. I used nascent RNA-Seq to characterize co-transcriptional splicing in S. pombe and developed two strategies to obtain single-molecule information on co-transcriptional splicing of endogenous genes: (1) with paired-end short read sequencing, I obtained the 3’ nascent transcript ends, which reflect the position of Pol II molecules during transcription, and the splicing status of the nascent RNAs. This is detected by sequencing the exon-intron or exon-exon junctions of the transcripts. Thus, this strategy links Pol II position with intron splicing of nascent RNA. The increase in the fraction of spliced transcripts with further distance from the intron end provides valuable information on when co-transcriptional splicing occurs. (2) with Pacific Biosciences sequencing (PacBio) of full-length nascent RNA, it is possible to determine the splicing pattern of transcripts with multiple introns, e.g. sequentially with transcription or also non-sequentially. Part of transcription termination is cleavage of the nascent transcript at the polyA site. The splicing status of cleaved and non-cleaved transcripts can provide insights into links between splicing and transcription termination and can be obtained from PacBio data. I found that co-transcriptional splicing in S. pombe is similarly prevalent to other species and that most introns are removed co-transcriptionally. Co-transcriptional splicing levels are dependent on intron position, adjacent exon length, and GC-content, but not splice site sequence. A high level of co-transcriptional splicing is correlated with high gene expression. In addition, I identified low abundance circular RNAs in intron-containing, as well as intronless genes, which could be side-products of RNA transcription and splicing. The analysis of co-transcriptional splicing patterns of 88 endogenous S. cerevisiae genes showed that the majority of intron splicing occurs within 100 nt downstream of the 3‘ SS. Saturation levels vary, and confirm results of a previous study. The onset of splicing is very close to the transcribing polymerase (within 27 nt) and implies that spliceosome assembly and conformational rearrangements must be completed immediately upon synthesis of the 3‘ SS. For S. pombe genes with multiple introns, most detected transcripts were completely spliced or completely unspliced. A smaller fraction showed partial splicing with the first intron being most often not spliced. Close to the polyA site, most transcripts were spliced, however uncleaved transcripts were often completely unspliced. This suggests a beneficial influence of pre-mRNA splicing for efficient transcript termination. Overall, sequencing of nascent RNA with the two strategies developed in this work offers significant potential for the analysis of co-transcriptional splicing, transcription termination and also RNA polymerase pausing by profiling nascent 3’ ends. I could define the position of pre-mRNA splicing during the process of transcription and provide evidence for fast and efficient co-transcriptional splicing in S. cerevisiae and S. pombe, which is associated with highly expressed genes in both organisms. Differences in S. pombe co-transcriptional splicing could be linked to gene architecture features, like intron position, GC-content and exon length.

Pre-mRNA (precursor messenger RNA) splicing is a fundamental process in eukaryotic gene expression. In order to catalyse the excision of the intervening intronic sequence between two exons, the spliceosome is assembled stepwise on the pre-mRNA substrate. This ribonucleoprotein machine is extremely dynamic: both its activation and the progression through the catalytic stages require extensive compositional and structural remodelling. The first part of this thesis aims at understanding how the spliceosome is activated after assembly. When this work was started, the GTPase Snu114 was thought to activate the helicase Brr2 to unwind the U4/U6 snRNA duplex, which ultimately leads to the formation of the spliceosome active site. To explore the role of Snu114, a complex built from Snu114 and a part of Prp8 was expressed and analysed in its natural context, bound to U5 snRNA. However, before I was able to obtain highly diffracting crystals, the structure of Snu114 was determined in the context of a larger spliceosomal complex by electron cryo-microscopy by competitors. Regardless, the role of Snu114 in spliceosome activation remains elusive. In a short section of this thesis, genetic and biochemical analysis suggest Snu114 to be a pseudo-GTPase, precluding a role for Snu114-catalyzed GTP hydrolysis in activation. The second and larger part of the thesis describes the development of a novel, biochemical method to analyse spliceosome remodelling events that are caused by the eight spliceosomal helicases. Purified spliceosomes assembled on a defined RNA substrate are analysed by UV crosslinking and next-generation sequencing, which allows for the determination of the RNA helicase binding profile at nucleotide resolution. In vitro spliceosome iCLIP (individual-nucleotide resolution UV crosslinking and immunoprecipitation) was initially developed targeting the helicase Prp16 bound to spliceosomal complex C. The obtained binding profile shows that Prp16 contacts the intron, about 15 nucleotides downstream of the branch in the intron-lariat intermediate. Our finding supports the model of Prp16 acting at a distance to remodel the RNA and protein interactions in the catalytic core and thereby it promotes the transition towards a conformation of the spliceosome competent for second step catalysis. Control experiments, which locate SmB protein binding to known Sm sites in the spliceosomal snRNAs, validated the method. Preliminary results show that in vitro spliceosome iCLIP can be adapted to analyse additional spliceosomal helicases such as Prp22. Finally, I performed initial experiments that give promising directions towards time-resolved translocation profiles of helicases Brr2 and Prp16.

<p>Pre-mRNA splicing and alternative pre-mRNA splicing are key regulatory steps controlling geneexpression in higher eukaryotes. The work in this thesis was focused on a characterization of thesignificance of exonic and intronic splicing enhancer elements for pre-mRNA splicing.</p><p>Previous studies have shown that removal of introns with weak and regulated splice sitesrequire a splicing enhancer for activity. Here we extended these studies by demonstrating thattwo "strong" constitutively active introns, the adenovirus 52,55K and the Drosophila Ftzintrons, are absolutely dependent on a downstream splicing enhancer for activity <i>in vitro</i>.</p><p>Two types splicing enhancers were shown to perform redundant functions as activators ofSplicing. Thus, SR protein binding to an exonic splicing enhancer element or U1 snRNP bindingto a downstream 5'splice site independently stimulated upstream intron removal. The datafurther showed that a 5'splice site was more effective and more versatile in activating splicing.Collectively the data suggest that a U1 enhancer is the prototypical enhancer element activatingsplicing of constitutively active introns.</p><p>Adenovirus IIIa pre-mRNA splicing is enhanced more than 200-fold in infected extracts. Themajor enhancer element responsible for this activation was shown to consist of the IIIa branchsite/polypyrimidne tract region. It functions as a Janus element and blocks splicing in extractsfrom uninfected cells while functioning as a splicing enhancer in the context of infected extracts.</p><p>Phosphorylated SR proteins are essential for pre-mRNA splicing. Large amount recombinantSR proteins are needed in splicing studies. A novel expression system was developed to expressphosphorylated, soluble and functionally active ASF/SF2 in <i>E. Coli</i>.</p>

Pre-mRNA splicing and alternative pre-mRNA splicing are key regulatory steps controlling geneexpression in higher eukaryotes. The work in this thesis was focused on a characterization of thesignificance of exonic and intronic splicing enhancer elements for pre-mRNA splicing. Previous studies have shown that removal of introns with weak and regulated splice sitesrequire a splicing enhancer for activity. Here we extended these studies by demonstrating thattwo "strong" constitutively active introns, the adenovirus 52,55K and the Drosophila Ftzintrons, are absolutely dependent on a downstream splicing enhancer for activity in vitro. Two types splicing enhancers were shown to perform redundant functions as activators ofSplicing. Thus, SR protein binding to an exonic splicing enhancer element or U1 snRNP bindingto a downstream 5'splice site independently stimulated upstream intron removal. The datafurther showed that a 5'splice site was more effective and more versatile in activating splicing.Collectively the data suggest that a U1 enhancer is the prototypical enhancer element activatingsplicing of constitutively active introns. Adenovirus IIIa pre-mRNA splicing is enhanced more than 200-fold in infected extracts. Themajor enhancer element responsible for this activation was shown to consist of the IIIa branchsite/polypyrimidne tract region. It functions as a Janus element and blocks splicing in extractsfrom uninfected cells while functioning as a splicing enhancer in the context of infected extracts. Phosphorylated SR proteins are essential for pre-mRNA splicing. Large amount recombinantSR proteins are needed in splicing studies. A novel expression system was developed to expressphosphorylated, soluble and functionally active ASF/SF2 in E. Coli.

Une analyse multiple des mutations, de l’expression des transcrits et de l’épissage alternatif a été réalisée dans des biopsies de lésions colorectales, correspondant à des stades variés de transformation, afin de rechercher des altérations qui caractériseraient la transformation de la muqueuse normale en adénome, puis en adénocarcinome. Cette analyse est basée sur l’utilisation de différentes technologies de puces à ADN. Des altérations spécifiques à chaque type de lésions colorectales ont été mises en évidence, démontrant que les adénomes et les adénocarcinomes sont des entités distinctes. Cependant, des altérations communes ont aussi été identifiées, confirmant que l’adénome est un état transitoire avant l’adénocarcinome. Une sélection clonale et des effets environnementaux sont sans doute à l’origine de la progression des adénomes en adénocarcinomes. Des voies de signalisation cellulaire caractéristiques de cette transformation ainsi qu’une classification des lésions colorectales ont été recherchées. Une signature de 40 transcrits a été identifiée, qui pourrait permettre de prédire la transformation des adénomes en adénocarcinomes. Des événements d’épissage alternatif ont aussi été détectés dans les adénomes, suggérant l’implication, à un stade précoce, de ces altérations dans le processus de cancérisation. Enfin, une puce à ADN « à façon » a été élaborée, qui s’inscrit dans une perspective d’appui à la mise en oeuvre de thérapeutiques anticancéreuses. Elle permet en effet d’analyser l’épissage alternatif des gènes codant les protéines cibles des nouvelles thérapies ciblées du cancer. / A genome-wide analysis of mutation, gene expression and alternative pre-mRNA splicing was performed in colorectal normal mucosa, adenoma and adenocarcinoma biopsy samples in order to look for some alterations that could characterize the stepwise “colorectal normal mucosa-adenoma-adenocarcinoma” transition. It was conducted through different microarray-based experiments. Alterations specific for either adenomas or adenocarcinomas were identified. Nevertheless, most deregulated genes in adenocarcinomas were shared between adenomas and adenocarcinomas, in agreement with the notion that adenomas are precursor lesions for adenocarcinomas. Adenomas may have different outcomes, depending on environment, some evolving towards cancer, while others could be prone to disappearance. Pathway enrichment in colorectal lesions and classification of colorectal lesions were investigated. A 40-gene set was identified as a gene expression signature that could help predicting patients, at time of adenoma ablation, with a risk for developing colorectal cancer. Splicing profiles were also identified in colorectal lesions, suggesting that alternative splicing may play a major role in cancer outcome. Finally, a custom microarray was designed with the aim to predict the response of patients before treatment. This custom microarray makes it possible to analyze transcript structure and levels for genes involved in the response to targeted anticancer therapies.

No description available.

Our laboratory delineated a role for alternative pre-mRNA splicing (AS) in triple negative breast cancer (TNBC). We found the translational regulator cytosolic polyadenylation element binding protein 2 (CPEB2) which has two isoforms, CPEB2A and CPEB2B, is alternatively spliced during acquisition of anoikis resistance (AnR) and metastasis. The splicing event which determines the CPEB2 isoform is via inclusion/ exclusion of exon four in the mature mRNA transcript. The loss of CPEB2A with a concomitant increase in CPEB2B is required for TNBC cells to metastasize in vivo. We examined RNAseq profiles of TNBC cells which had CPEB2 isoforms specifically downregulated to examine the mechanism by which CPEB2 isoforms mediate opposing effects on cancer-related phenotypes. Downregulation of the CPEB2B isoform inhibited pathways driving the epithelial-to-mesenchymal transition (EMT) and hypoxic response, whereas downregulation of the CPEB2A isoform did not have this effect. Specifically, CPEB2B functioned as a translational activator of TWIST1 and HIF1a. Functional studies showed that specific downregulation of either HIF1α or TWIST1 inhibited the ability of CPEB2B to induce AnR and drive metastasis. The mechanism governing inclusion/ exclusion of exon 4 was determined to be serine/ arginine-rich splicing factor 3 (SRSF3). Binding of SRSF3 to a consensus sequence within CPEB2 exon 4 promoted its inclusion in the mature mRNA, and mutation of this sequence abolished association of SRSF3 with exon 4. SRSF3 expression was upregulated in TNBC cells upon acquisition of AnR correlating with a reduction in the CPEB2A/B ratio. Importantly, downregulation of SRSF3 by siRNA in these cells induced the exclusion of exon 4. Downregulation of SRSF3 also reversed the CPEB2A/B ratio in a wild-type CPEB2 exon 4 minigene construct, but not a mutant CPEB2 minigene with the SRSF3 RNA cis-element ablated. Physiologic studies demonstrated SRSF3 downregulation ablated AnR in TNBC cells, and was “rescued” by ectopic expression of CPEB2B. Importantly, biostatistical analysis of The Cancer Genome Atlas database showed a positive relationship between alterations in SRSF3 expression and lower overall survival in TNBC. Overall, this study demonstrates that SRSF3 modulates CPEB2 AS to induce the expression of the CPEB2B isoform that drives TNBC phenotypes correlating with aggressive human breast cancer.

<p>ASF/SF2 is an essential splicing factor, required for constitutive splicing, and functioning as a regulator of alternative splicing. ASF/SF2 is modular in structure and contains two amino-terminal RNA binding domains (RBD1 and RBD2), and a carboxy-terminal RS domain. The results from my studies show that the different activities of ASF/SF2 as a regulator of alternative 5’ and 3’ splice site selection can be attributed to distinct domains of ASF/SF2.</p><p>I show that ASF/SF2-RBD2 is both necessary and sufficient to reproduce the splicing repressor function of ASF/SF2. A SWQDLKD motif was shown to be essential for the splicing repressor activity of ASF/SF2. In conclusion, this study demonstrated that ASF/SF2 encodes for distinct domains responsible for its function as a splicing enhancer (the RS domain) or a splicing repressor (the RBD2) protein. Using a model transcript containing two competing 3’ splice sites it was further demonstrated that the activity of ASF/SF2 as a regulator of alternative 3’ splice site selection was directional: i.e. resulting in RS or RBD1 mediated activation of upstream 3’ splice site selection while simultaneously causing an RBD2 mediated repression of downstream 3’ splice site usage.</p><p>In alternative 5’ splice site selection, the RBD2 alone was sufficient to reproduce the activity of the full-length protein as an inducer of proximal 5’ splice site usage, while RBD1 had the opposite effect and induced distal 5’ splice site selection. The conserved SWQDLKD motif and the RNP-1 type RNA recognition motif in ASF/SF2-RBD2 were both essential for this induction. The activity of the ASF/SF2-RBD2 domain as a regulator of alternative 5’ splice site was shown to correlate with the RNA binding capacity of the domain.</p><p>Collectively, my results suggest that the RBD2 domain in ASF/SF2 plays the most decisive role in the alternative 5’ and 3’ splice site regulatory activities of ASF/SF2.</p>

ASF/SF2 is an essential splicing factor, required for constitutive splicing, and functioning as a regulator of alternative splicing. ASF/SF2 is modular in structure and contains two amino-terminal RNA binding domains (RBD1 and RBD2), and a carboxy-terminal RS domain. The results from my studies show that the different activities of ASF/SF2 as a regulator of alternative 5’ and 3’ splice site selection can be attributed to distinct domains of ASF/SF2. I show that ASF/SF2-RBD2 is both necessary and sufficient to reproduce the splicing repressor function of ASF/SF2. A SWQDLKD motif was shown to be essential for the splicing repressor activity of ASF/SF2. In conclusion, this study demonstrated that ASF/SF2 encodes for distinct domains responsible for its function as a splicing enhancer (the RS domain) or a splicing repressor (the RBD2) protein. Using a model transcript containing two competing 3’ splice sites it was further demonstrated that the activity of ASF/SF2 as a regulator of alternative 3’ splice site selection was directional: i.e. resulting in RS or RBD1 mediated activation of upstream 3’ splice site selection while simultaneously causing an RBD2 mediated repression of downstream 3’ splice site usage. In alternative 5’ splice site selection, the RBD2 alone was sufficient to reproduce the activity of the full-length protein as an inducer of proximal 5’ splice site usage, while RBD1 had the opposite effect and induced distal 5’ splice site selection. The conserved SWQDLKD motif and the RNP-1 type RNA recognition motif in ASF/SF2-RBD2 were both essential for this induction. The activity of the ASF/SF2-RBD2 domain as a regulator of alternative 5’ splice site was shown to correlate with the RNA binding capacity of the domain. Collectively, my results suggest that the RBD2 domain in ASF/SF2 plays the most decisive role in the alternative 5’ and 3’ splice site regulatory activities of ASF/SF2.